title: [Graft-versus-host disease (GvHD) - an update. Part 2: prognosis and therapy of GvHD].
abstract: Graft-versus-host disease (GvHD) remains one of the major complications after allogeneic stem cell transplantation (SCT) and is responsible for morbidity, mortality and decrease in quality of life of patients after SCT. The most important preventive approach is the selection of a donor with best possible HLA compatibility between donor and recipient. Basic prophylaxis of acute GvHD begins already prior to transplantation and usually consists of cyclosporine with or without methotrexate. In the past few years, many new therapies have been introduced for the treatment of acute and chronic GvHD. Extracorporeal photopheresis (ECP), for example, represents a promising treatment option for acute and chronic GvHD with very few side effects. For chronic GvHD mTOR inhibitors (sirolimus, everolimus) may replace calcineurin-inhibitors with the advantage of not inducing malignant skin tumors. Guidelines are available ort he management of acute and chronic GvHD. While pathophysiology, classification and skin manifestations of GvHD have been already presented in the first part of this article, this second part covers the prognosis, prevention and treatment of GvHD.
authors.affiliation: Klinik und Poliklinik für Dermatologie, Universität Regensburg.
authors.forename: R
authors.initials: R
authors.lastname: Travnik
authors.forename: M
authors.initials: M
authors.lastname: Beckers
authors.forename: D
authors.initials: D
authors.lastname: Wolff
authors.forename: E
authors.initials: E
authors.lastname: Holler
authors.forename: M
authors.initials: M
authors.lastname: Landthaler
authors.forename: S
authors.initials: S
authors.lastname: Karrer
mesh_terms: D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D002280:Basal Cell Carcinoma / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy; D002423:Cause of Death; D002908:Chronic Disease; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D006086:Graft vs Host Disease / Q000175:diagnosis* / Q000401:mortality / Q000517:prevention & control / Q000628:therapy*; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008212:Lymphocyte Depletion; D009894:Opportunistic Infections / Q000401:mortality; D017893:Photopheresis; D010787:Photosensitivity Disorders / Q000175:diagnosis / Q000401:mortality / Q000517:prevention & control / Q000628:therapy; D011379:Prognosis; D012307:Risk Factors; D012594:Scleroderma, Localized / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy; D012871:Skin Diseases / Q000175:diagnosis* / Q000401:mortality / Q000517:prevention & control / Q000628:therapy*; D012878:Skin Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D033581:Stem Cell Transplantation; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases